Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron and keeping the price target at $767.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Terence Flynn has given his Buy rating due to a combination of factors surrounding Regeneron’s innovative advancements in the anticoagulation market. The company’s Phase 2 study results for their Factor XI antibodies, REGN7508 and REGN9933, demonstrated promising efficacy in preventing postoperative venous thromboembolism (VTE) with a favorable safety profile, showing no major bleeding incidents. This positions Regeneron well in a market where current anticoagulants are underutilized due to bleeding risks.
Furthermore, Regeneron’s strategic focus on addressing the unmet needs in anticoagulation, particularly in conditions like atrial fibrillation and VTE, highlights a significant market opportunity. The genetic validation supporting the Factor XI program and the advancement into Phase 3 trials underscore the potential for these therapies to capture a substantial share of the $20 billion global market. Flynn’s rating reflects confidence in Regeneron’s ability to leverage these developments to drive future growth.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $850.00 price target.